Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Expression analysis of microRNA and lncRNA in visceral adipose tissue of obese and non-obese individuals

Бейркдар А., Иванощук ДЕ., Тузовская ОВ., Широкова НС., Каштанова ЕВ., Полонская ЯВ.

Prospective Study with a reported sample of 70 on Type 2 Diabetes, published in Vavilovskii Zhurnal Genet Selektsii (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Vavilovskii Zhurnal Genet Selektsii (2025)
Reported sample size
70
Source database
Europe PMC
PMID
40567589
PMCID
PMC12188000
DOI
10.18699/vjgb-25-48

Abstract (original English)

Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) play important roles in all biological processes, including adipogenesis, lipid metabolism, and insulin response. Analyzing expression patterns of lncRNAs and miRNAs in human visceral fat tissue can enhance our understanding of their roles in metabolic disorders. Our research aims to investigate the expression of lncRNAs (ASMER1, SNHG9, P5549, P19461, and GAS5) and miRNAs (miR-26A, miR-222, miR-221, and miR-155) in visceral adipose tissues of individuals with abdominal obesity (n = 70) compared to their levels in non-obese participants (n = 31), using Real-Time PCR. Among the tested miRNAs, only miR-26A was significantly downregulated in the visceral adipose tissue of obese individuals, with no significant change in the expression of miR- 26A in obese people with or without type 2 diabetes. Similarly, of the tested lncRNAs, only GAS5 showed significantly higher expression levels in obese patients with type 2 diabetes (T2D) (n = 10) compared to obese patients without T2D (n = 60). To test possible interactions between the analyzed non-coding RNAs, we used Spearman's bivariate correlation test. GAS5 expression levels showed a weak negative correlation (p < 0.05, rs = 0.25) with miR-155 levels in obese patients only. Conversely, a strong positive correlation (p <0.01, rs = 0.92) between SNHG9 and GAS5 was found in the non-obese

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research